COST-EFFECTIVENESS OF SWITCHING STRATEGIES FROM A 7-VALENT TO A 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE

被引：1
|
作者：
Claes, C. [1 ]
Mittendorf, T. [1 ]
Kuchenbecker, U. [2 ]
Rose, M. [3 ]
Reinert, R. R. [4 ]
机构：
[1] Leibniz Univ Hannover, Hannover, Germany
[2] Wyeth Pharma, Munster, Germany
[3] Goethe Univ Frankfurt, Frankfurt, Germany
[4] Wyeth Vaccines Res, Paris, France
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)75100-7
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A425 / A425
页数：1
相关论文
共 50 条
  • [41] Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
    Rajeev Dhere
    Vistasp Sethna
    Hitesh Malviya
    Rajeshwari Adhiseshan
    [J]. Infectious Diseases and Therapy, 2022, 11 : 1297 - 1299
  • [42] Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
    Dhere, Rajeev
    Sethna, Vistasp
    Malviya, Hitesh
    Adhiseshan, Rajeshwari
    [J]. INFECTIOUS DISEASES AND THERAPY, 2022, 11 (03) : 1297 - 1299
  • [43] Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea
    Choi, Min-Joo
    Kang, Shin-On
    Oh, Jin-Jeong
    Park, Seong-Beom
    Kim, Min-Ja
    Cheong, Hee-Jin
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (08) : 1914 - 1922
  • [44] Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
    Gouveia, Miguel
    Jesus, Goncalo
    Ines, Monica
    Costa, Joao
    Borges, Margarida
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (04) : 850 - 858
  • [45] Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK
    Jiang, Yiling
    Gauthier, Aline
    Keeping, Sam
    Carroll, Stuart
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (06) : 913 - 927
  • [46] Changes in the pneumococcal disease-related hospitalisations in Spain after the replacement of 7-valent by 13-valent conjugate vaccine
    L. Georgalis
    A. Mozalevskis
    M. V. Martínez de Aragón
    M. Garrido-Estepa
    [J]. European Journal of Clinical Microbiology & Infectious Diseases, 2017, 36 : 575 - 583
  • [47] Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany
    Kieninger, Dorothee M.
    Kueper, Kathrin
    Steul, Katrin
    Juergens, Christine
    Ahlers, Norbert
    Baker, Sherryl
    Jansen, Kathrin U.
    Devlin, Carmel
    Gruber, William C.
    Emini, Emilio A.
    Scott, Daniel A.
    [J]. VACCINE, 2010, 28 (25) : 4192 - 4203
  • [48] 13-valent pneumococcal conjugate vaccine in Africa
    Cohen, Robert
    Levy, Corinne
    [J]. LANCET GLOBAL HEALTH, 2017, 5 (03): : E244 - E245
  • [49] COST-EFFECTIVENESS OF PAEDIATRIC PNEUMOCOCCAL VACCINATION IN THE NETHERLANDS; AN UPDATE FOR THE 7-VALENT AND FORECAST FOR THE 10-AND 13-VALENT PNEUMOCOCCAL CONJUGATED VACCINES (PCVS)
    Rozenbaum, M.
    Sanders, E. A.
    van Hoek, A.
    Jansen, A. G.
    van de Ende, A.
    Rodenburg, G.
    van den Dobbelsteen, G.
    Hak, E.
    Postma, M. J.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A294 - A294
  • [50] COST-EFFECTIVENESS OF 13-VALENT VERSUS 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINE USE IN CROATIA NATIONAL VACCINATION PROGRAM
    Tichopad, A.
    Pecen, L.
    Roberts, C. S.
    Uglesic, L.
    Tesovic, G.
    Rogier, K.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A608 - A608
12345